Sign in
Taking peoplePhase 1

How the body processes inhaled colistimethate in healthy adults and bronchiectasis patients

Tests how colistimethate sodium moves through the body in healthy adults and adults with bronchiectasis.

Key facts

Who runs it
Zambon S.p.A.
Where
Bialystok and Jozefow, PolandSee the 2 sitesAlso in 2 other countries, 3 sites
Registry title
A Two-part study to learn the amount of polymyxin E1 in the body over time formed after a single inhaled dose of colistimethate sodium (CMS) in healthy adults (Part 1) and after single inhaled and vein-infused doses of CMS in adults with non‑cystic fibrosis bronchiectasis (NCFB) (Part 2)
Status
Recruiting
Phase
Phase 1
People taking part
55 people, planned
Started
2 Nov 2026
Expected to end
31 May 2027
Type of study
Interventional
Record updated
28 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy adults (Part 1) and adults with non-cystic fibrosis bronchiectasis (Part 2). It studies how the body handles colistimethate sodium (CMS) over time.

Age
18 years or older
Sex
All sexes can join

Where in Poland

Also in 2 other countries, 3 sites

  • Centrum Medycyny Oddechowej Mroz sp. j.Bialystok, PolandNot yet recruiting
  • Biokinetica S.A.Jozefow, PolandNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Plain-language title
How the body processes inhaled colistimethate in healthy adults and bronchiectasis patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
28 October 2026